Vanda Pharmaceuticals (VNDA) Non-Current Deffered Revenue (2010 - 2014)

Vanda Pharmaceuticals (VNDA) has 5 years of Non-Current Deffered Revenue data on file, last reported at $3.1 million in Q4 2014.

• For the quarter ending Q4 2014, Non-Current Deffered Revenue fell 95.12% year-over-year to $3.1 million; the trailing twelve-month figure through Dec 2014 stood at $3.1 million (down 95.12% YoY), and the FY2014 full-year result was $3.1 million, down 95.12% from the prior year.
• Non-Current Deffered Revenue slipped to $3.1 million in Q4 2014, from $36.2 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $143.9 million in Q4 2010 to a low of $461000.0 in Q4 2011.
• A 5-year average of $46.8 million and a median of $19.7 million in 2014 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue slumped 99.68% in 2011 and surged 19482.43% in 2012, its largest moves.
• Tracing VNDA's Non-Current Deffered Revenue over 5 years: stood at $143.9 million in 2010, then tumbled by 99.68% to $461000.0 in 2011, then surged by 19482.43% to $90.3 million in 2012, then decreased by 29.67% to $63.5 million in 2013, then tumbled by 95.12% to $3.1 million in 2014.
• Business Quant data shows VNDA's Non-Current Deffered Revenue at $3.1 million in Q4 2014, $36.2 million in Q3 2014, and $2.9 million in Q2 2014.